Ir
Ordenar por:
títulofecha de envíofecha de publicación
Orden:
ascendentedescendente
Resultados:
51020406080100
Modificar
Mostrando ítems 1-2 de 2
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
journal article
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung